Ascletis Pharma Inc. (ASCLETIS-B) has filed a Next Day Disclosure Return with the Hong Kong Stock Exchange detailing further progress under its June 2026 share-repurchase mandate.

Key Points • Latest transaction: On 12 October 2026 the company repurchased 200,000 ordinary shares on the Exchange at prices ranging between HKD 6.68 and HKD 7.09, for a total consideration of HKD 1.37 million. The volume-weighted average price was HKD 6.85 per share. • Cumulative 2026 activity: Including the most recent purchase, Ascletis has bought back 2.35 million shares since 30 June 2026. All acquired shares are designated for cancellation but had not yet been cancelled as of 12 October 2026. • Utilisation of mandate: The 2.35 million shares repurchased represent 0.22 % of the company’s issued share capital (excluding treasury shares) at the time the 29 June 2026 mandate was granted. The board is authorised to repurchase up to 106.14 million shares, leaving more than 100 million shares, or 99.8 % of the mandate, still available. • Share capital position: Issued shares (excluding treasury stock) stood unchanged at 1.05 billion as of both 30 September and 12 October 2026. Treasury shares remained at 5.78 million, keeping total shares outstanding at 1.06 billion. • Post-repurchase restrictions: In accordance with Hong Kong listing rules, Ascletis is restricted from issuing new shares or transferring treasury shares until 11 November 2026.

The company confirms all repurchases complied with Main Board Rule 10.06 requirements and that no material changes have occurred in the explanatory statement filed on 8 June 2026.